65,437 trials
Breast Cancer
Primary: Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies — 71.4; 72.9 Percent reduction
Mild Cognitive Impairment
Primary: Episodic Memory Assessed by the Cogstate Alzheimer's Battery — -0.0746; 0.0700; 0.0593; 0.5137 z score
Relapsing Multiple Sclerosis (RMS)
Primary: Adjusted Annualized Relapse Rate (ARR) in Adult Group — 0.018 relapses per participant-year
Systemic Lupus Erythematosus
Primary: SLICC Score — 62; 56; 46; 41 participants — p=0.72
Graft Versus Host Disease (GVHD)
Primary: Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment — 60.0; 45.1 percentage of participants — p=0.034
Hypotension · Labor Complication
Primary: Number of Patients With Maternal Hypotension Requiring Treatment — 6; 11; 48; 27 Participants
Hypertension
Primary: Number of Participants Who Talk to Research Pharmacist — 20 Participants
Pre-Eclampsia
Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio
Pressure Sore
Primary: Percent Change in Wound Area — -78.5; -65.1 percentage change
Anemia, Iron Deficiency · Hyperphosphatemia · Renal Insufficiency, Chronic
Primary: Number of Participants Achieving a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality — 35; 46 Participants — p=.1602
Carcinoma, Non-Small-Cell Lung · Melanoma
Primary: Number of Participants With an Adverse Event (AE) — 131 Participants
ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs) — 31; 63; 43; 16 Participants
Online Training for Therapists
Primary: Feasibility of Recruitment — 61; 62 Participants
Type 1 Diabetes · Hypoglycemia
Primary: Difference in Percentage of Time in Target Glucose Range (PG: 3.9 - 10.0 mmol/l) During and for 1-hour After Dynamic Physical Exercise Between Visit B and C — 100; 100…
Myelofibrosis
Primary: Most Common Treatment Related Adverse Events — 1; 1; 2; 1 participants